ANDA 204906, held by Rising Pharmaceuticals. Ondansetron Hydrochloride.
As of Nov 21, 2026, ANDA 204906 (Ondansetron Hydrochloride), held by Rising Pharmaceuticals, was first approved by FDA on Jul 31, 2017, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 31, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ondansetron HydrochlorideEQ 2MG BASE/ML · injectable;injection | Ondansetron Hydrochloride | Discontinued |
| Oct 23, 2025 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jan 3, 2024 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 31, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters